Skip to main content

Table 2 Risk of appropriate implantable cardioverter-defibrillator therapy in obese versus non-obese patients in ICD arm

From: Effect of obesity on the effectiveness of cardiac resynchronization to reduce the risk of first and recurrent ventricular tachyarrhythmia events

 

Number events

Adjusted HR (95 % CI) p value

VT/VF

124

1.33

(0.91–1.96)

0.144

VT/VF/death

159

1.25

(0.89–1.75)

0.199

VT/VF greater than 200 bpm

62

0.96

(0.57–1.64)

0.880

Shock delivered for VT/VF

76

0.96

(0.67–1.79)

0.745

  1. After adjustment for: race (Black/African American), age at enrollment, creatinine ≥1.4, female sex, left ventricle end diastolic volume index, myocardial infarction prior to enrollment, enrollment NYHA classification, prior hospitalization during prior year, QRS <150, ventricular arrhythmias requiring treatment prior to enrolment